Advertisement
Pharma/Biotech News
Subscribe to Pharma/Biotech News
View Sample

FREE Email Newsletter

Daily news and top headlines for drug research professionals

Discovery Helps to Spot What Makes a Good Drug

October 2, 2014 10:03 am | News | Comments

A new test developed by researchers from The University of Manchester could revolutionize the discovery of new prescription drugs. The test will help determine which drugs are unlikely to work at an early stage, speeding up the time it takes to make safe and effective medicines available. Read more...

Drugmaker Submits Harder-to-Abuse Zohydro to FDA

October 2, 2014 9:33 am | by Matthew Perrone, AP Health Writer | News | Comments

The maker of the much-debated painkiller Zohydro is seeking approval of a harder-to-abuse version of the drug which, if approved, could replace the currently marketed version of the pill by next spring. Read more...          

Merck Completes Sale of Consumer Unit to Bayer

October 1, 2014 3:52 pm | News | Comments

Drugmaker Merck said that it completed the sale of its consumer care business, which makes products including Claritin allergy medication and Coppertone sun-care line, to German health care company Bayer for $14.2 billion. Read more...     

Advertisement

Portola Pharmaceuticals Announces Phase 3 ANNEXA-A Data

October 1, 2014 3:45 pm | News | Comments

Portola Pharmaceuticals announced that its first Phase 3 study of andexanet alfa, a potential universal Factor Xa inhibitor antidote and U.S. Food and Drug Administration-designated breakthrough therapy, met its primary and secondary endpoints with high statistical significance. Read more...

Ebola Treatment Makers Rise After First U.S. Case

October 1, 2014 3:29 pm | News | Comments

Shares of several drugmakers developing potential vaccines or treatments for the deadly Ebola virus rose in premarket trading, continuing a run that started after federal officials confirmed that the first case of the disease has been diagnosed in the United States. Read more... 

Daiichi Sankyo Submits Cravit sNDA in Japan

October 1, 2014 12:57 pm | News | Comments

Daiichi Sankyo Co. Ltd. announced that it and its domestic generic subsidiary, Daiichi Sankyo Espha Co. Ltd., have submitted a supplemental New Drug Application (sNDA) in Japan for the synthetic broad-spectrum oral antibacterial agent Cravit Tablets. Read more...

Immunovaccine Announces Plans for Phase 2 Clinical Trial of DPX-Survivac

October 1, 2014 11:14 am | News | Comments

Immunovaccine Inc. (“Immunovaccine” or “IMV”), a clinical stage vaccine and immunotherapy company, provided a clinical development program update for DPX-Survivac, the company’s lead cancer vaccine candidate. Read more...

Drug and Device Firms Paid $3.5B to Care Providers

October 1, 2014 10:34 am | by Ricardo Alonso-Zaldivar | News | Comments

From research grants to travel junkets, drug and medical device companies paid doctors and leading hospitals billions of dollars last year, the government disclosed in a new effort to spotlight potential ethical conflicts in medicine. Read more...

Advertisement

Targeted Treatment Could Halt Womb Cancer Growth

October 1, 2014 10:06 am | News | Comments

A drug which targets a key gene fault could halt an aggressive womb cancer and shrink tumours, according to research published in the British Journal of Cancer. Read more...

J&J Buying Alios for $1.75B

September 30, 2014 3:03 pm | News | Comments

Johnson & Johnson is buying the biopharmaceutical company Alios BioPharma Inc. for about $1.75 billion. Alios is a privately held company that focuses on developing therapies for viral diseases. Read more...         

Viagra Ads Target Women for First Time

September 30, 2014 1:52 pm | by Linda Johnson, AP Business Writer | News | Comments

The maker of the world's top-selling erectile dysfunction drug on Tuesday will begin airing the first Viagra TV commercial in America that targets the less-obvious sufferers of the sexual condition: women. Read more...

Sanofi, Regeneron Announce Positive Dupilumab Results

September 30, 2014 11:00 am | News | Comments

Regeneron Pharmaceuticals and Sanofi announced that a Phase 2a study of dupilumab, an investigational therapy that blocks IL-4 and IL-13 signaling, met all primary and secondary endpoints in patients with moderate-to-severe chronic sinusitis with nasal polyps (CSwNP) who did not respond to intranasal corticosteroids. Read more...

Pfizer, Kyowa Hakko Kirin Partner on Immuno-Oncology Combo Study

September 30, 2014 10:49 am | News | Comments

Pfizer Inc. and Kyowa Hakko Kirin announced that they've entered into an agreement to explore the therapeutic potential of the combination of Pfizer’s PF-05082566 with Kyowa Hakko Kirin’s anti-CCR4 antibody mogamulizumab. Read more...         

Advertisement

NIH Awards Seven New Vaccine Adjuvant Discovery Contracts

September 30, 2014 10:37 am | News | Comments

The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, has awarded seven research contracts to discover and characterize new adjuvants, or substances formulated as part of vaccines to enhance their protective ability. Read more...

Gov't to Reveal Drug Company Payments to Doctors

September 30, 2014 10:27 am | by Ricardo Alonso-Zaldivar | News | Comments

Striving to shine a light on potential ethical conflicts in medicine, the Obama administration is releasing data on drug company payments to tens of thousands of individual doctors. Read more...                

Takeda, Seattle Genetics Receive Positive Data from Lymphoma Trial

September 30, 2014 10:02 am | News | Comments

Seattle Genetics and Takeda Pharmaceutical Co. Ltd. announced that patients with Hodgkin lymphoma (HL) who received Adcetris (brentuximab vedotin) as consolidation therapy immediately following an autologous stem cell transplantation (ASCT) lived significantly longer without disease progression compared to patients who received placebo. Read more...

Array's Melanoma Drug Promising in Phase 2

September 29, 2014 3:46 pm | News | Comments

Final results from a Phase 2 trial of binimetinib in patients with advanced NRAS mutant melanoma were presented at the European Society for Medical Oncology (ESMO) Annual Meeting in Madrid, Spain. Invented by Array BioPharma Inc. and licensed to Novartis in 2010, binimetinib is a small molecule selective inhibitor of the kinases MEK1 and MEK2. Read more...

Tonix Fibromyalgia Pain Drug Misses Endpoint in Phase 2b

September 29, 2014 3:28 pm | News | Comments

Tonix Pharmaceuticals announced results of the Phase 2b BESTFIT study of TNX-102 SL as a chronic bedtime treatment for fibromyalgia. The study did not achieve statistical significance in the primary efficacy endpoint of change in average daily pain score at week 12. Read more...

Insys Therapeutics' Cannabidiol Receives FDA Orphan Drug Designation

September 29, 2014 3:23 pm | News | Comments

Insys Therapeutics, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to its pharmaceutical cannabidiol (CBD) for the treatment of glioma. Read more...             

Amag Pharma to Acquire Lumara Health for $675M

September 29, 2014 3:09 pm | News | Comments

Shares of anemia treatment maker Amag Pharmaceuticals soared Monday after it announced plans to buy Lumara Health in a cash-and-stock deal that eventually could be worth more than $1 billion. Read more...             

Combo Treatment Ups PFS in Advanced Melanoma Patients

September 29, 2014 3:07 pm | News | Comments

Shares of Exelixis jumped Monday before markets opened and after the drugmaker said its treatment for a deadly form of skin cancer fared better than another drug in a late-stage clinical study. Read more...

Bristol-Myers Squibb Gets Positive Results for Nivoluma

September 29, 2014 2:58 pm | News | Comments

Bristol-Myers Squibb Co. announced positive results from CheckMate-037, a Phase 3 randomized, controlled open-label study of Opdivo (nivolumab), an investigational PD-1 immune checkpoint inhibitor, versus investigator’s choice chemotherapy (ICC) in patients with advanced melanoma. Read more...

Perrigo Acquires Women's Healthcare Products from Lumara

September 29, 2014 11:02 am | News | Comments

Perrigo Company plc announced that it has signed a definitive agreement to acquire a portfolio of women's healthcare products from Lumara Health, Inc., a privately-held, Chesterfield, Missouri-based specialty pharmaceutical company, for $82 million in cash. Read more...

Janssen's Rezolsta Receives Positive Opinion from CHMP

September 29, 2014 10:49 am | News | Comments

Janssen announced that the CHMP of the European Medicines Agency has granted a Positive Opinion recommending Rezolsta (darunavir/cobicistat) in combination with other antiretroviral medicinal products for the treatment of HIV-1 infection in adults aged 18 years or older. Read more...

EMA Validates Marketing Authorization Application for Nivoluma

September 29, 2014 10:31 am | News | Comments

Bristol-Myers Squibb announced that the European Medicines Agency has validated for review the Marketing Authorization Application for nivolumab in non-small cell lung cancer– the first completed regulatory submission for a PD-1 immune checkpoint inhibitor in this tumor type. Read more...

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading